Molecular Partners AG
MOLN
Rang în acțiuni
#19481
Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to... Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and bringing to market novel therapeutic proteins. Leveraging its proprietary DARPin® platform, the company is advancing a diverse pipeline of product candidates. Key among these is Abicipar, a DARPin-based treatment currently in Phase III clinical development for significant ophthalmic conditions like neovascular wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Additionally, their portfolio features multi-specific DARPin candidates targeting infectious diseases, such as MP0420 and MP0423, both designed to combat the SARS-CoV-2 virus (COVID-19). In the oncology space, Molecular Partners is advancing several programs: MP0310, in Phase Ia for immuno-oncology; MP0317, a Phase I tumor-localized immune agonist engineered to activate immune cells within tumors; and MP0274, also in Phase I, aimed at HER2-positive cancers. Further early-stage assets include MP0533, a CD3 T cell candidate for acute myeloid leukemia, and MP0250, which targets vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and human serum albumin (HSA) to enhance therapeutic half-life. The company actively collaborates with leading pharmaceutical companies. Notable alliances include a partnership with Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; agreements with Amgen SA and Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc. They also maintain relationships with various other third-party collaborators. Established in 2004, Molecular Partners AG is headquartered in Schlieren, Switzerland.
Preț acțiune
$3.98
Ultima sincronizare: 2026-10-19
Capitalizare de piață
$152.44M
Schimbare (1 zi)
-1.29%
Schimbare (1 an)
14.68%
Țară
CH
Tranzacționează Molecular Partners AG (MOLN)
Categorie
Healthcare
Capitalizarea de piață a Molecular Partners AG(MOLN)
Capitalizare de piață: $152.44M
În anul October 2026, Molecular Partners AG are o capitalizare de piață de $152.44M. Acest lucru face ca Molecular Partners AG să fie a 19481st-a cea mai valoroasă companie din lume, conform datelor noastre. Capitalizarea bursieră reprezintă valoarea totală de piață a acțiunilor în circulație ale unei companii listate și este utilizată frecvent pentru a măsura valoarea unei companii.
Istoricul capitalizării de piață a Molecular Partners AG din 2016 până în 2026
MOLN în comparație cu top 5 cele mai populare stocks
